**Annual Report of Testing Methods**

**Annual Assessment**

Annually, each funded laboratory is required to report to CDC a summary of its testing methods. These summary reports have to be submitted by email communication to ARLN\_DHQP@cdc.gov at the beginning of each calendar year.

|  |  |
| --- | --- |
|  | Method(s)  |
| Organism identification[e.g., MALDI, VITEK, API20E, Biochemical, Other (specify)] |  |
| Antimicrobial susceptibility testing (AST)[e.g., Etest, Broth Microdilution, Disk Diffusion, Digital Dispenser; Other (specify)] |  |
| Carbapenemase production testing[e.g., CarbaNP; mCIM; Other (specify)] |  |
| Carbapenemase gene identification [e.g., Cepheid Gene Xpert; CDC PCR, Streck ARM-D; Nanosphere Verigene; In- House PCR; or other (specify)] |  |
|  | Gene Targets Detected |
| Carbapenemase genes targets [e.g., KPC, NDM, OXA-23, OXA-48, VIM, IMP-1 group, Expanded IMP variants (CDC assay)] |  |
| Other gene targets [e.g., *mcr* 1, *mcr* 2, Other (specify)] |  |
|  | Whole genome sequencing capacities |
| Number of MiSeq, HiSeq, NextSeq, or other sequencing platforms  |  |
| PacBio capacity |  |
| DNA extraction method(s) |  |
| Description of fragment analyzers, tape stations, bioanalyzers, library prep kits, and QC equipment  |  |
| Bioinformatics capacities and/or staff  |  |